Advanced Clinical Software Incorporates National Cancer Institute Reports within Study Manager Clinical Trial Software.

SEATTLE -- Advanced Clinical Software, Inc. (ACS) announced today that it has incorporated several key reports for the National Cancer Institute (NCI) within the latest release of its industry-leading Study Manager(TM) clinical trial management system. The availability of these reports will save clinical researchers time by allowing them to automatically generate NCI reports using data stored within the Study Manager software instead of preparing the reports manually.

Research centers conducting oncology studies must submit summary reports to the NCI yearly. These reports enable the NCI to track statistics on cancer research, including how much research is being done, who is conducting it, where it is being conducted, anatomic cancer sites involved, funding, and other data. Although useful, these reports are time-consuming to prepare. The latest release of Study Manager will be able to populate NCI Summary 2, Summary 3, and Summary 4 reports with data that researchers have already entered into the software.

"These reports alleviate the need to enter data into two different places and will reduce the burden on researchers who are already overwhelmed with clinical responsibilities," said Bruce Schatzman, President of ACS. "The NCI reports are part of a set of recently added product features designed specifically for cancer research that will give ACS an additional competitive edge."

Now in its 12th version, the Web-based Study Manager clinical trial management system allows researchers to closely monitor clinical trial operations and access key information such as patient visit tracking, scheduling information, financial data, enrollment progress, and task management in a timely and secure manner.

Based in Seattle, Washington, ACS is a privately held company.